Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
SY SYK STRYKER CORP FY ended Jan 31, 2026 | $330.69 | $126.84B | $140.75B | $25.12B | $6.29B | $3.25B | 39.37x | 5.05x | 22.38x |
ZB ZBH ZIMMER BIOMET HOLDINGS, INC. FY ended Feb 10, 2026 | $100.91 | $19.25B | $23.27B | $8.23B | $1.92B | $705.10M | 28.43x | 2.34x | 12.09x |
MD MDT Medtronic plc FY ended Jun 12, 2026 | $91.23 | $116.78B | $133.87B | $36.36B | $9.78B | $4.80B | 24.46x | 3.21x | 12.69x |
JN JNJ JOHNSON & JOHNSON FY ended Feb 06, 2026 | $268.04 | $645.95B | $703.36B | $94.19B | $37.95B | $26.80B | 24.30x | 6.86x | 17.67x |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 16.49x | 4/4 | -$311.05M | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 4.36x | 4/4 | $3.59B | $88.11 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 29.14x | 4/4 | -$2.69B | — | Target fundamentals do not produce a usable positive equity value. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
SY SYK STRYKER CORP FY ended Jan 31, 2026 | $330.69 | $126.84B | $140.75B | $25.12B | $6.29B | $3.25B | 39.37x | 5.05x | 22.38x |
ZB ZBH ZIMMER BIOMET HOLDINGS, INC. FY ended Feb 10, 2026 | $100.91 | $19.25B | $23.27B | $8.23B | $1.92B | $705.10M | 28.43x | 2.34x | 12.09x |
MD MDT Medtronic plc FY ended Jun 12, 2026 | $91.23 | $116.78B | $133.87B | $36.36B | $9.78B | $4.80B | 24.46x | 3.21x | 12.69x |
JN JNJ JOHNSON & JOHNSON FY ended Feb 06, 2026 | $268.04 | $645.95B | $703.36B | $94.19B | $37.95B | $26.80B | 24.30x | 6.86x | 17.67x |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 16.49x | 4/4 | -$311.05M | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 4.36x | 4/4 | $3.59B | $88.11 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 29.14x | 4/4 | -$2.69B | — | Target fundamentals do not produce a usable positive equity value. |
